Abstract
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have